Case Studies

Challenge: A biopharma company asked Alacrita to provide expert input on the clinical development of a microbiome therapeutic (LBP, live biotherapeutic product) in the context of first line and...

Challenge: A clinical stage microbiome company was developing a microbiome therapeutic for the treatment of recurrent C. Difficle infection (rCDI). The company was progressing through clinical...

Challenge: On behalf of a European pharmaceutical company, one of Alacrita’s professionals acted as medical director for the registration of a new agent in a neuroendocrine indication in territories...

Challenge A glycan biomarker research company with a proprietary platform offering biomarker discovery and characterization, diagnostic development and commercialization asked Alacrita to help them...

Challenge: Our client was developing oncolytic viruses for treating a rare form of brain cancer. Its lead product had been successfully evaluated in a Phase I dose-escalation study. Direct injection...

Challenge: A Swiss biopharma company was developing a therapeutic for a severe orphan disorder. The company had successfully obtained Breakthrough Therapy Designation by the FDA and PRIME status by...

Challenge: A young biotech company with a portfolio of clinical and pre-clinical stage bispecific antibodies (BsAb) to treat various cancers was in the process of completing a Series A funding round....

Challenge: A Swiss biopharma company was developing a therapeutic for a severe orphan disorder. The company had successfully obtained Breakthrough Therapy Designation by the FDA and PRIME status by...

Challenge An early stage, European cell therapy company focused on developing novel off-the-shelf NK cell therapy solutions for the treatment of a variety of cancers had developed a platform...

Challenge: Our client planning to develop and commercialize a preclinical compound for metabolic disorders. The product had a wide therapeutic potential for disorders associated with disruption of...

Challenge A start-up US biotech developing a non-opioid analgesic drug and delivery device was preparing to raise its first round of external funding. They engaged Alacrita to help frame the target...

Challenge Our client was a start-up looking to raise external venture capital funding for development of a biosensor for early detection of opioid overdose. The company had drafted a business plan...